Eli Lilly reported second-quarter results before the US open on Wednesday, and at first glance they read as a continuation of a familiar story: revenue of $22.97 billion, up 48 percent year over year, comfortably ahead of the roughly $20.5 to $20.9 billion analysts had penciled in. Full-year guidance went up again. The shares rose about 3.3 percent in early trading to around $1,158, leaving the market value just short of a trillion dollars.
The headline is not the interesting part. The interesting part is the clause the company itself uses to explain it. That 48 percent came from a 60 percent increase in volume, partially offset by a 13 percent decrease in realized prices. That is an unusual construction for a company this size. The fastest-growing large-cap in American healthcare is currently growing by selling more cheaply. Anyone still reading the obesity market with the mental tools of 2023 and 2024, when scarcity set the terms, is going to misjudge the next several quarters in a specific and predictable direction.
The numbers behind the number
Non-GAAP earnings came in at $8.38 per share, up 33 percent; on a reported basis it was $7.94, up 26 percent. Consensus sat somewhere between $6.01 and $6.58 depending on whose survey you use, so even by the standards of a company that has beaten in almost every quarter for two years, the gap is unusually wide. Key products contributed $15.7 billion of the total.
Mounjaro, the tirzepatide diabetes brand, carried the quarter at $9.94 billion, up 91 percent. The split matters more than the total. Revenue outside the United States rose 172 percent to $5.2 billion, which means that on the arithmetic, more than half of Mounjaro’s revenue came from outside its home market for the first time. Zepbound, the obesity label, brought in $4.93 billion in the US, up 44 percent — and in that same sentence Lilly names lower realized prices as the drag, explicitly including previously announced reductions to cash-pay prices.
Chief executive David Ricks summarized it plainly in the release: Lilly’s momentum continues, the company delivered 48 percent revenue growth. True enough. It just does not describe where the growth came from.
Why prices fell, and exactly where
The 13 percent is not an accident and not a competitive mishap. It is the arithmetic result of two deliberate decisions. The first is domestic. Lilly has cut the cash-pay price of its incretin franchise in stages and built a direct-to-consumer channel priced to compete with the compounding pharmacies and telehealth sellers that anchored expectations during the shortage years. Running alongside that is an entire price cascade: a sharply lower list price scheduled for January 2027, negotiated rates for Medicare and Medicaid, and a capped copay for severe obesity. Every one of those moves buys reach and costs margin. None of them is reversible in practice.
The second decision is Chinese. Mounjaro was added to the National Reimbursement Drug List in the first quarter of 2026. That is the standard bargain in a state-negotiated health system: accept a substantial discount, receive access to a patient population that self-pay economics could never have reached. Lilly names precisely this as the reason realized prices outside the US fell — in the same breath as the 172 percent increase that it enabled. These are not two facts. They are one fact seen from two sides.
What this marks is a transition the market was always going to have to make. For two years the binding constraint was manufacturing capacity, measured in how many pens could be filled and finished. In that world there was no reason to think about price, because everything the plants produced was sold. That world is over. The binding constraint now is what a payer is willing to pay, and payers do not respond to capacity expansion.
Margin is the more honest indicator
If you take only one number away from this report, do not take the 48 percent. Take the operating margin: 39.1 percent, down from 44.1 percent a year earlier. Five full percentage points, in a record revenue quarter. Part of that traces to the one-time charges discussed below, but not all of it. The remainder is exactly the mix the revenue line describes — more units on worse terms, and a rising share of the business that is international and reimbursement-funded rather than American and self-paid.
This is not a warning about Lilly. A company compounding revenue at 48 percent on a roughly 40 percent operating margin is one of the more remarkable things in the current market. It is a warning about a particular way of extrapolating that growth. When volume rises and price falls, the reported growth rate is the difference between two opposing forces — and differences move faster than either of their components.
Novo Nordisk supplied the counter-proof a day earlier
The strongest evidence for this reading did not come from Lilly at all. It came on Tuesday from the competition. Novo Nordisk reported adjusted operating profit of 33.389 billion Danish kroner. Adjusted sales grew 7 percent at constant exchange rates and adjusted operating profit 11 percent. The company raised its full-year outlook — to a range of zero to minus 6 percent for both measures. The shares fell anyway, because the guidance was not enough for the market.
Here is the part that matters. That same company holds the volume record. The Wegovy pill recorded roughly 2.9 million prescriptions in the second quarter, more than 5 million since launch, and weekly scripts above 265,000 in the week ending 17 July. Novo describes it as the strongest GLP-1 volume launch the United States has ever seen. The quarterly revenue attached to that record was 3.141 billion kroner.
Lilly’s own pill, Foundayo — orforglipron, approved on 1 April 2026 as the first oral GLP-1 for weight loss that can be taken at any time of day without food or water restrictions — looks considerably weaker in the script data. In the week ending 26 June it stood at roughly 19,830 total prescriptions, a level Novo’s pill reached within two to three weeks of its own launch. Analysts put the second-quarter contribution at about $146 million.
So two findings sit side by side and only appear to contradict each other. Novo has the strongest volume launch in the category’s history and grew 7 percent. Lilly is losing the oral prescription race and grew 48 percent. Volume and value have come apart in this market. Anyone using the weekly script trackers as a trading signal is now measuring something meaningfully different from what lands in the income statement.
The second calculation: guidance up, guidance number down
There is a second place in this report where the headline says the opposite of what happened. On revenue it is straightforward: the full-year range moved from $82–85 billion to $85–87 billion. On earnings it gets strange. Lilly raised its underlying non-GAAP EPS guidance by $2.78 at the midpoint — and in the same sentence set $3.03 of acquired in-process research and development charges against it. Net of that, the printed range falls to $35.50 to $36.50. The business got better and the published number got worse.
Specific transactions sit behind that. The quarter carried $2.8 billion in acquired IPR&D charges, against $154 million a year earlier, primarily from the acquisitions of Orna Therapeutics and Ajax Therapeutics. On top of that came $703 million in asset impairment, restructuring and other special charges, mostly accelerated vesting of employee equity awards plus acquisition and integration costs tied to closing the purchases of Kelonia Therapeutics and Centessa Pharmaceuticals.
Four deals in one quarter is not coincidence. It is the logical continuation of the first finding. When price stops doing the work, the pipeline has to. Lilly is converting the cash flow from a maturing product cycle into options on the next one. Whether that pays off will be settled in years rather than quarters — but under US accounting rules the bill hits the earnings line immediately and in full, which is why a better business can produce a worse forecast.
What this means for a US portfolio
Three practical consequences follow for American investors, and the most obvious one is the least useful. Buying Lilly on a 48 percent print at nearly a trillion dollars of market value means paying for the growth rate that the same press release just explained is partly price-financed. That is not a reason to avoid the stock; it is a reason to underwrite it on volume, indications and pipeline rather than on the headline growth rate.
The second is that a falling unit price moves value toward the companies paid per unit rather than per molecule. That is the injectable components and delivery complex — West Pharmaceutical Services with elastomer components and seals, Becton Dickinson in syringes and pen needles, and the contract manufacturers that run fill-finish capacity. The economics are thinner than pharma economics, but they capture volume growth without absorbing the price concession. Industry estimates put Novo and Lilly’s combined cartridge consumption at roughly 3.8 billion units in 2024, and the pharmaceutical cartridge market is projected to roughly double from about $2.15 billion in 2026 to $4.44 billion by 2035.
The third is the number worth tracking, and it is not the list price. Watch the cash-pay price. The self-pay tier is where the marginal American patient actually transacts, and it is where the compounders set the anchor during the shortage. The scheduled January 2027 list-price reduction is a headline; the cash channel is the market. Access mechanics matter here too: Foundayo had coverage at two of the three largest pharmacy benefit managers by mid-May and gained Medicare access through the CMS GLP-1 Bridge program from 1 July.
One tax note, because it changes what kind of position this is. A thesis built on volume expansion, indication expansion and reimbursement decisions plays out over years, not weeks. Held longer than a year, gains are taxed at long-term capital gains rates topping out at 20 percent; traded around each quarterly print, the same gains are ordinary income at rates up to 37 percent. The trading approach has to clear that spread before it beats simply owning the compounding.
The case against this reading
The most honest counterargument is that falling prices alongside sharply rising volume is exactly what a healthy mass market does, and absolute profit can keep climbing through it for years. A price cut that unlocks a doubling of treated patients is the correct commercial decision even when it costs margin. Forty-eight percent growth is not a distress signal; it is the opposite.
Second, the reimbursement side is the strongest refutation of the pessimistic case. Once these molecules are funded through cardiovascular, renal and hepatic indications rather than treated as lifestyle products, budgets open that are structurally closed to a self-pay market. A lower price that is guaranteed and reimbursed can be worth more than a higher price paid by a smaller, more discretionary population.
Third, comparing the two oral launches on script counts alone is unfair. Prices, access routes and coverage status differ. A few months of lag in a market forecast to reach well over $100 billion by 2030 settles nothing.
The rule worth keeping
The transferable tool from this quarter is a decomposition that applies to any growing company and is performed surprisingly rarely: how much of the growth is volume, how much is price, and which way is each moving? Four combinations exist and they are worth very different amounts. Both rising is the strongest position and it is rare. Volume up, price down is Lilly today — healthy, but margin-consuming. Volume down, price up is a company raising the bill on its installed base, and it almost always ends badly. Both falling ends the discussion.
Lilly sits clearly on the good side of that ledger. Volume is carrying the growth, price is braking it, and the revenue guidance raise shows management actively seeking the trade. What holders should be clear about is that the coming quarters will not be decided by how many pens the plants can fill. They will be decided by what a payer agrees to pay — a different question, with different opponents, and a price no chief executive sets alone.
The market backdrop for all this is unusually friendly. The S&P 500 closed Tuesday at 7,736.52, above 7,700 for the first time and at a record; the Dow finished at 54,085.88, its first close above 54,000; the Nasdaq Composite ended at 26,584.99. On Wednesday the four-day rally lost momentum. Oil kept sliding — Brent below $79, West Texas Intermediate toward $75 — as the prospect of a temporary agreement to reopen the Strait of Hormuz drained the risk premium. The long end stays elevated, with the ten-year Treasury near 4.63 percent and the thirty-year around 5.25 percent, after the Federal Reserve held at 3.50 to 3.75 percent in late July with three dissents favoring a hike. In that rate environment, every growth rate gets tested for how much of it actually arrives as profit. Which is precisely why the 13 percent line matters more than the 48 percent one.
Try TradingView Free for 30 Days
Plus get a $15 discount on your first subscription through this link.
